BioSpace News Archive

It’s not what you say sometimes but what you do. What are your non-verbal cues saying to a potential employer? Learn what to do to present yourself as the best candidate for the job, without ever saying a word.

PharmaCyte Biotech recently discussed its options and plans for a Phase IIb clinical trial of its Cell-in-a-Box technology in pancreatic cancer.

Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.

Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases.

The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod.

After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.

Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.

Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC).

Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.

Following a two week trial in Orange County, Florida, a jury entered its verdict on February 23, 2018, against Florida Hospital for retaliating against one of its heart and lung transplant surgeons by wrongfully terminating him after he objected to and refused to participate in Florida Hospital’s violation of Florida’s patient safety laws. Ahmad Chaudhry, M.D., brought his case pursuant to Florida’s Whistleblower Act.